Logo
x

Search

Subscribe Now

 P-III

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

  • December 13, 2024
Galderma Publishes the P-III (OLYMPIA 1) Trial of Nemolizumab for Prurigo Nodularis in JAMA Dermatology

Galderma Publishes the P-III (OLYMPIA 1) Trial of Nemolizumab for Prurigo Nodularis in JAMA Dermatology

  • November 29, 2024
Telix Pharmaceuticals Reports the First Patient Dosing in P-III (ZIRCON-CP) Trial of TLX250-CDx for Kidney Cancer Imaging in China

Telix Pharmaceuticals Reports the First Patient Dosing in P-III (ZIRCON-CP) Trial of TLX250-CDx for Kidney Cancer Imaging in China

  • November 28, 2024
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

  • October 30, 2024
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

  • October 28, 2024
Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

  • October 28, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.